January 15, 2019
Cascadia Capital, an investment bank serving middle market clients globally, today announced it acted as the exclusive financial advisor to OraHealth Corporation Inc. (“Orahealth”), a market leading provider of OTC all-natural oral care products that relieve specific oral health issues such as dry mouth, in its merger with Quest Products, a portfolio company of Promus Equity.
With this merger, Quest will add the OraCoat® brand of oral care products and its flagship product, XyliMelts® for Dry Mouth, to its portfolio of category leading brands, including Clinere, Alocane, and Provent. XyliMelts® employ patented technology backed by research and medical science to safely prevent dry mouth both during the day and while a user sleeps via all-natural, non-acidic oral-adhering discs that slowly release safe ingredients.
“I chose Paul Vander Vort to be my advisor based on a referral from a trusted colleague on the positive experience and outcome he had when he sold his business,” commented Jeff Haley, founder and President of OraHealth, referring to the sale of Serengeti Law to Thomson Reuters. “Cascadia successfully guided me through the transaction in its entirety, ensuring I received the best possible result for my company. I would highly recommend Cascadia to any business owner evaluating their strategic options.”
Paul Vander Vort, Managing Director, Cascadia Capital, added, “Jeff’s passion for the business, and his understanding of the M&A process and level-headedness throughout made him a pleasure to work with and made achieving this outcome particularly fulfilling. This transaction was especially rewarding for Jeff and his team, as it allows them to continue to accelerate the marketing, distribution, and sales of current and new OraHealth products.”
For more information, please contact the Cascadia OraHealth deal team:
Paul Vander Vort